OBESTIN-30

Post-LOE

phentermine hydrochloride

Ferndale Pharma Group

ANDAORALCAPSULE

Approved

Apr 1981

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

OBESTIN-30 (phentermine hydrochloride) by Ferndale Pharma Group is obesity, amphetamine (d- and d l l-amphetamine). Approved for hypertension. First approved in 1981.

Drug data last refreshed 20h ago

Mechanism of Action

obesity, amphetamine (d- and d l l-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system…

Indications (1)

hypertension

Company

Worked on OBESTIN-30 at Ferndale Pharma Group? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.